Kanghui Bullish On Joint Implants Despite Looming Price Cuts; Mindray Undercutting U.S. Competition: China Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Regulatory headwinds and price cuts led to a massive slowdown in China’s pharmaceutical industry in Q3, but China’s device makers are still enjoying fast growth.